Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis

European Journal of Heart Failure

Volumn 18, Issue 10, 2016, Pages 1238-1243

  Solomon, Scott D ^a   Claggett, Brian ^a   McMurray, John J V ^b   Hernandez, Adrian F ^c   Fonarow, Gregg C ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c DUKE UNIVERSITY   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

Heart failure; Meta analysis; Neprilysin; Renin angiotensin system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PLACEBO; RENIN; SACUBITRIL PLUS VALSARTAN; SINORPHAN;

ADVERSE DRUG REACTION; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DRUG EFFICACY; ENZYME INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HORMONAL REGULATION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84989872584     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.603     Document Type: Article

References (26)

1. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 2005;67:1723–1730.
2. Stevens TL, Burnett JC Jr, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995;95:1101–1108.
3. Good JM, Peters M, Wilkins M, Jackson N, Oakley CM, Cleland JG. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol 1995;25:1273–1281.
4. Cleland JG, Swedberg K, for the International Ecadotril Multi-Centre Dose-Ranging Study Investigators. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet 1998;351:1657–1658.
5. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT.Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607–613.
6. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71:1501–1507.
7. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 2016;130:57–77.
8. Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol 2014;176:630–639.
9. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615–620.
10. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920–926.
11. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103–111.
12. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin–angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2014;2:663–670.
13. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255–1266.
14. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387–1395.
15. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062–1073.
16. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
17. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. EQUATOR website. http://www.equator-network.org/reporting-guidelines/prisma/. 26 June 2014.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Cin Trials 1986;7:177–188.
19. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
20. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand SL, Ortiz E, Peterson ED, Roach WH Jr, Sacco RL, Smith SC Jr, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu PB, Qaseem A, Sayre MR, Somerfield MR. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:213–265.
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016; May 20 [Epub ahead of print].
22. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
23. Howlett JG, Chan M, Ezekowitz JA, Harkness K, Heckman GA, Kouz S, Leblanc MH, Moe GW, O'Meara E, Abrams H, Ducharme A, Grzeslo A, Hamilton PG, Koshman SL, Lepage S, McDonald M, McKelvie R, Rajda M, Swiggum E, Virani S, Zieroth S. The Canadian Cardiovascular Society Heart Failure Companion: bridging guidelines to your practice. Can J Cardiol 2016;32:296–310.
24. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947–955.
25. McMurray JJ, Packer M, Solomon SD. Neprilysin inhibition for heart failure. N Engl J Med 2014;371:2336–2337.
26. Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, Jhee S, Gevorkyan H, Rajman I. The effect of LCZ696 on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 2016;81:878–890.